Search

Your search keyword '"Gilmer JF"' showing total 61 results

Search Constraints

Start Over You searched for: Author "Gilmer JF" Remove constraint Author: "Gilmer JF"
61 results on '"Gilmer JF"'

Search Results

1. Pharmacological characterization of nanoparticle-induced platelet microaggregation using quartz crystal microbalance with dissipation: comparison with light aggregometry

2. Secondary (iso)BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions.

Catalog

Books, media, physical & digital resources

3. Impact of Deoxycholic Acid on Oesophageal Adenocarcinoma Invasion: Effect on Matrix Metalloproteinases.

4. Novel Barbiturate-Nitrate Compounds Inhibit the Upregulation of Matrix Metalloproteinase-9 Gene Expression in Intestinal Inflammation through a cGMP-Mediated Pathway.

5. Cardioprotective effect of MMP-2-inhibitor-NO-donor hybrid against ischaemia/reperfusion injury.

6. Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis: effect on inflammation-related genes.

7. Unconjugated secondary bile acids activate the unfolded protein response and induce golgi fragmentation via a src-kinase-dependant mechanism.

8. Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults.

9. A fluorescent analogue of tauroursodeoxycholic acid reduces ER stress and is cytoprotective.

10. A Central Role for Monocyte-Platelet Interactions in Heart Failure.

11. Novel Selective Butyrylcholinesterase Inhibitors Incorporating Antioxidant Functionalities as Potential Bimodal Therapeutics for Alzheimer's Disease.

12. Matrix metalloproteinases in inflammatory bowel disease: an update.

13. Part Two: Evaluation of N-methylbupropion as a Potential Bupropion Prodrug.

14. Synthesis, screening and pharmacokinetic evaluation of potential prodrugs of bupropion. Part one: in vitro development.

15. Nitric oxide-matrix metaloproteinase-9 interactions: biological and pharmacological significance--NO and MMP-9 interactions.

16. Mechanisms of platelet-stimulated colon cancer invasion: role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway.

17. New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid.

18. Synthesis and biological evaluation of Foscan® bile acid conjugates to target esophageal cancer cells.

19. Ursodeoxycholic acid attenuates colonic epithelial secretory function.

20. A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib.

21. MMP inhibition by barbiturate homodimers.

22. A methodology for detection and quantification of esterase activity.

23. Structure requirements for anaerobe processing of azo compounds: implications for prodrug design.

24. Azo-reductase activated budesodine prodrugs for colon targeting.

25. Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.

26. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?

27. Design of barbiturate-nitrate hybrids that inhibit MMP-9 activity and secretion.

28. New fluorescent bile acids: synthesis, chemical characterization, and disastereoselective uptake by Caco-2 cells of 3-deoxy 3-NBD-amino deoxycholic and ursodeoxycholic acid.

29. Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets.

30. A double prodrug system for colon targeting of benzenesulfonamide COX-2 inhibitors.

31. N-substituted homopiperazine barbiturates as gelatinase inhibitors.

32. Investigation into drug release from colon-specific azoreductase-activated steroid prodrugs using in-vitro models.

33. Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators.

34. Advances in bile acid medicinal chemistry.

35. The aqueous stability of bupropion.

36. Bile acid toxicity structure-activity relationships: correlations between cell viability and lipophilicity in a panel of new and known bile acids using an oesophageal cell line (HET-1A).

37. Isosorbide-2-benzyl carbamate-5-salicylate, a peripheral anionic site binding subnanomolar selective butyrylcholinesterase inhibitor.

38. Isosorbide-based cholinesterase inhibitors; replacement of 5-ester groups leading to increased stability.

39. Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.

40. Design, synthesis, and pharmacological effects of a cyclization-activated steroid prodrug for colon targeting in inflammatory bowel disease.

41. Discovery of a "true" aspirin prodrug.

42. Isosorbide-2-carbamate esters: potent and selective butyrylcholinesterase inhibitors.

43. Pharmacological effects of a novel isosorbide-based butyrylcholinesterase inhibitor.

44. Novel isosorbide di-ester compounds as inhibitors of acetylcholinesterase.

45. Prodrugs for amines.

46. Matrix metalloproteinases in platelet function: coming of age.

47. Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirins.

48. Beta-aminoketones as prodrugs with pH-controlled activation.

49. Chiral separation and identification of beta-aminoketones of pharmacological interest by high performance liquid chromatography and capillary electrophoresis.

50. Novel isosorbide-based substrates for human butyrylcholinesterase.